Dostarlimab and Pembrolizumab in Endometrial Cancer Treatment

Efficacy and Safety

The American Society of Clinical Oncology recommends dostarlimab and pembrolizumab as treatment options for dMMR/MSI-H endometrial cancer, with dostarlimab demonstrating a 61.4% 2-year PFS rate in the RUBY trial 1
The National Comprehensive Cancer Network suggests that both dostarlimab and pembrolizumab have robust activity as monotherapy in dMMR/MSI-H endometrial cancer, with an objective response rate of 42.3% for dostarlimab in the GARNET trial 3
The European Society for Medical Oncology notes that pembrolizumab plus lenvatinib has established efficacy in pMMR/MSS endometrial cancer, with a median PFS of 6.6 months in the KEYNOTE-775 trial 3
The American College of Obstetricians and Gynecologists recommends biomarker testing, including MMR IHC and MSI testing, to determine eligibility for dostarlimab and pembrolizumab treatment 2
The Society of Gynecologic Oncology suggests that dostarlimab plus chemotherapy may be particularly effective in dMMR/MSI-H patients, with a substantial PFS benefit in the RUBY trial 1

The US Food and Drug Administration approved dostarlimab for dMMR recurrent or advanced endometrial cancer that progressed on or after platinum-based therapy, with a strength of evidence level of 1 5
The FDA approved pembrolizumab for MSI-H/dMMR solid tumors, including endometrial cancer, that progressed following prior treatment, with a strength of evidence level of 1 2
The FDA approved pembrolizumab plus lenvatinib for advanced endometrial cancer that is not MSI-H/dMMR after platinum-based chemotherapy, with a strength of evidence level of 1 5